At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
BF2.649 +1 moredrug
Likely dose
BF2.649 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, Study to Demonstrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder
University of Texas Southwestern Medical Center·interventional·Posted Jun 4, 2008·Updated Apr 23, 2019
In Brief
A Phase 2 clinical trial evaluating BF2.649 and Placebo for Schizophrenia. Completed, enrolled 52 participants across 2 sites.
Detailed Summary
To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsBioprojet, Stanley Medical Research Institute
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionOct 2011
TodayJul 2026
First PostedJun 4, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.1 years ago
Interventions
BF2.649drug
up to 20mg per day
Placebodrug
up to 20mg per day